WHO recognition affirms MHRA’s commitment to regulatory excellence, innovation and global collaboration
Similar Posts
Notice: Medicines: terminated and cancelled manufacturing and wholesale dealer licences
UK companies who have their licence to manufacture or wholesale medicines terminated and cancelled.
Decision: Marketing authorisations Granted in 2026
Marketing authorisations Granted in 2026.
MHRA CEO Lawrence Tallon welcomes Life Sciences Sector Plan
The Life Sciences Sector plan was released today (16 July 2025)
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
Guidance: Medical devices: examples of reportable incidents
Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
MHRA announces proposals to improve access to world’s best medical devices for patients and to boost economic growth in Britain’s med tech sector
The MHRA has now published the government’s response to its public consultation on future routes to market for medical devices – designed to modernise regulation